Bevacizumab in combination with chemotherapy and erlotinib by itself have each demonstrated a substantial improvement in survival when utilized for the treatment of patients with advanced non-small cell lung cancer. Researchers in this phase III, multicenter scientific trial were hopeful that the combination of the two agents that focus on different pathways would present a survival benefit. 1000 and thirty six patients were signed up for the analysis between June 2005 and April 2008.* Treating traumatic brain injury. Moderated by Dr. Timothy A. Pedley, chairman and professor of the Division of Neurology at Columbia University College of Physicians and Surgeons, and neurologist-in-chief at NewYork-Presbyterian Hospital/Columbia University INFIRMARY, the panel session will concentrate on neurological aspects of trauma-related brain damage and methods to assess and address it. * Addressing PTSD and related disorders – – including depression, stress, suicide and substance abuse – – among veterans and their families.